Massive Bio
AI-powered platform connecting cancer patients and oncologists to clinical trials while enabling pharmaceutical firms to expedite drug development.
AI-powered platform connecting cancer patients and oncologists to clinical trials while enabling pharmaceutical firms to expedite drug development.
Massive Bio is an AI-powered platform connecting cancer patients and oncologists to clinical trials, while enabling pharmaceutical firms to expedite drug development. Launched in 2015, the company has made significant strides in the AI, Big Data, Biotechnology, Health Care, Health and Wellness, Pharmaceutical, and Machine Learning industries. The recent $17.00M Series B investment on 02 June 2022 from Revo Capital, ImpactAssets, Catalytic Impact Foundation, DEG, SiteGround, Kenan Turnacioglu, IFC Asset Management Company, Charles and Lynn Schusterman Family Philanthropies underscores investor confidence. Massive Bio's platform facilitates access to patient data from community practices, optimizes trial enrollment through technology and sub-specialist expertise, and resolves "last mile" issues for trial enrollment. This positions them as a trusted partner for pharmaceutical companies and CROs, showcasing potential for further impact in the healthcare and pharmaceutical sectors.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $17.00M | 8 |
|
02 Jun 2022 |
| Seed Round | $2.82M | 3 |
|
03 Nov 2020 |
| Seed Round | $2.00M | 2 |
|
02 May 2019 |
| Seed Round | $1.10M | 1 |
|
16 Jul 2018 |
| Seed Round | $900.00K | 2 |
|
04 Jul 2016 |
No recent news or press coverage available for Massive Bio.
We care about your data, and we'd love to use cookies make your experience better.
